2-Chloroethanol

CAS RN: 107-07-3

Health Effects

0.2.1 SUMMARY OF EXPOSURE
  • 0.2.1.1 ACUTE EXPOSURE
    • A) SEVERE - poisoning may result in nausea, vomiting, coma, seizures, tachycardia, gastrointestinal bleeding, metabolic acidosis, hypotension, and respiratory failure. Human fatal poisonings have occurred by the oral, inhalational, and dermal exposure routes. Ethylene chlorohydrin has a moderate to high order of acute toxicity. Reported deaths have been due to metabolic acidosis and respiratory failure.
    • B) MILD/MODERATE - exposure may cause nausea, vomiting, tachycardia, tachypnea, weakness, lethargy, transient confusion, sore throat or mouth pain, dizziness, transient hypertension, hypokalemia and transient renal insufficiency.
    • C) DERMAL - Absorption through intact skin is good and dermal exposure may cause systemic toxicity. It is an eye irritant, but not a skin sensitizer. Ethylene chlorohydrin penetrates ordinary rubber gloves.
    • D) ONSET - Toxic effects generally develop within 2 hours after exposure.
    • E) When heated to decomposition, ethylene chlorohydrin releases highly toxic chloride and phosgene fumes.
0.2.3 VITAL SIGNS
  • 0.2.3.1 ACUTE EXPOSURE
    • A) Tachypnea, hypotension, and irregular pulse may occur.
0.2.4 HEENT
  • 0.2.4.1 ACUTE EXPOSURE
    • A) This substance is highly irritating to the eyes and mucous membranes of the nose and throat. Visual disturbances and hemorrhages of the conjunctiva have been reported in exposed workers.
0.2.5 CARDIOVASCULAR
  • 0.2.5.1 ACUTE EXPOSURE
    • A) Circulatory shock and sinus tachycardia may occur. Necrobiotic and dystrophic changes and dilation of the right side of the heart have been reported with severe poisoning.
0.2.6 RESPIRATORY
  • 0.2.6.1 ACUTE EXPOSURE
    • A) Respiratory tract irritation, cough, and respiratory failure have been reported. Noncardiogenic pulmonary edema, capillary engorgement, and interstitial hemorrhages of the lungs may occur.
0.2.7 NEUROLOGIC
  • 0.2.7.1 ACUTE EXPOSURE
    • A) Incoordination, vertigo, confusion, paresthesias, spastic contracture of the hands, seizures, cerebral edema, giddiness, headache, CNS depression, weak or absent reflexes, paralysis, and mental disturbances may occur.
0.2.8 GASTROINTESTINAL
  • 0.2.8.1 ACUTE EXPOSURE
    • A) Nausea and vomiting may occur.
0.2.9 HEPATIC
  • 0.2.9.1 ACUTE EXPOSURE
    • A) Liver glutathione depletion, inactivation of drug-metabolizing enzymes, hemorrhage, liver damage, and hepatic necrosis may occur.
    • B) In rats, oral ethanol administered concomitantly lessened the early effects on liver glutathione.
0.2.10 GENITOURINARY
  • 0.2.10.1 ACUTE EXPOSURE
    • A) Hematuria, slight albuminuria, polyuria, cloudy swelling of the tubules, intense engorgement, dystrophic and necrobiotic changes, degeneration of the kidneys, disorders in excretion of electrolytes and nitrogen, and hemorrhages of the kidney may occur.
0.2.11 ACID-BASE
  • 0.2.11.1 ACUTE EXPOSURE
    • A) Metabolic acidosis may occur.
0.2.14 DERMATOLOGIC
  • 0.2.14.1 ACUTE EXPOSURE
    • A) Human fatalities have occurred following dermal exposure.
    • B) Erythema, nuclear pyknosis, blisters, and petechial skin hemorrhages have been reported in experimental animal studies.
0.2.16 ENDOCRINE
  • 0.2.16.1 ACUTE EXPOSURE
    • A) Disturbances in pancreatic function have occurred in experimental animals.
0.2.20 REPRODUCTIVE HAZARDS
  • A) Skeletal defects and developmental abnormalities of the hepatobiliary system have been noted in experimental animals.
  • B) Ethylene chlorohydrin was fetotoxic in mice. A significant reduction in maternal weight gain and a decrease in fetal body weight and liver weight was noted in experimental animals.
0.2.21 CARCINOGENICITY
  • 0.2.21.1 IARC CATEGORY
    • A) IARC Carcinogenicity Ratings for CAS107-07-3 (International Agency for Research on Cancer (IARC), 2016; International Agency for Research on Cancer, 2015; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2010a; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2008; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2007; IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, 2006; IARC, 2004):
      • 1) Not Listed
  • 0.2.21.2 HUMAN OVERVIEW
    • A) No evidence of carcinogenicity has been found.
0.2.22 GENOTOXICITY
  • A) DNA repair, chromosome aberrations, and mutations have been noted (RTECS , 2001; Lewis & Sr, 2000).
Find more information on this substance at: PubChem, PubMed